FDA LABEL RECORD
Liraglutide
LIRAGLUTIDE. FDA prescribing information for this product, as published on the retrieval date below.
AS THE LABEL RECORDS IT
Product details
| Brand name | Liraglutide |
|---|---|
| Generic name | LIRAGLUTIDE |
| Labeller | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) |
| Route | SUBCUTANEOUS |
| Label version | 1 |
| Effective | 2024-06-05 |
| Retrieved by this site | 2026-10-03 |
| Full label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a36b801-41e2-2eed-e063-6294a90a6f27 |
INDICATIONS AND USAGE
Quoted from the FDA label
Liraglutide injection is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus Limitations of Use: Liraglutide injection should not be used in patients with type 1 diabetes mellitus. Liraglutide injection contains liraglutide and should not be coadministered with other liraglutide-containing products.
What this page is
A reproduction of a public FDA label record. Everything quoted above is the labeller's wording as published by the FDA, not this site's. Nothing here is regulatory, legal or medical advice, and a label being reproduced says nothing about whether a product is available in any particular country. Labels are revised often; the retrieval date above says when this copy was taken, and the full current label is at the link.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.